THE GOVERNMENT OF THE UNITED STATES OF AMERICA ASREPRESENTED BY THE SECRETARY OF THE DEPARTMENT OFHEALTH AND HUMAN SERVICES
发明人:
CHANG, GWONG-JEN, J.,CRILL, WAYNE, D.,HUGHES, HOLLY, R.,DAVIS, BRENT, S.
申请号：
EP12841016
公开号：
EP2768847A4
申请日:
2012.10.18
申请国别(地区):
EP
年份:
2015
代理人:
摘要：
Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus. The dengue virus E-glycoprotein polypeptides have amino acid substitutions at residues corresponding to position 106, 107, 310 and 311, and either position 364 or position 389 of dengue serotype 1 (DENV-1) E-glycoprotein. The provided E-glycoprotein polypeptides optionally further include mutations corresponding to positions 468, 478, 482 and 487 of DENV-1 E-glycoprotein.
